The dose-response relationship in a fixed-activity approach generally applied in the treatment of differentiated thyroid cancer is assessed using 124 I PET/CT. 
INTRODUCTION
Radioiodine therapy is the standard adjuvant therapy, after total thyroidectomy in patients with differentiated thyroid cancer (DTC) (1, 2) . The purpose of radioiodine therapy is twofold: ablation of thyroid remnants and treatment of radioiodine avid metastases.
The generally accepted threshold for lesion absorbed dose (AD) to achieve high therapy response is 85 Gy for metastases and 300 Gy for thyroid remnants, respectively (3, 4) . To predict therapy response, a reliable AD estimation requires, inter alia, accurate lesion volume determination, which is hampered by the often small lesion volumes with respect to the spatial resolution of 131 I scintigraphy and lesion segmentation difficulties encountered in ultrasonography (US), computed tomography (CT) or other imaging modalities (1, 5) . As a result, personalized radioiodine therapy based on lesion dosimetry is not globally adopted. In general, a fixed 131 I activity is administered based on disease characteristics and patient age with the risk of under-or overtreatment (6) .
Several groups have concluded that quantitation of 124 I positron emission tomography (PET) images is feasible (7) (8) (9) (10) (11) . Compared to 131 I single photon emission tomography (SPECT), 124 I PET imaging offers a higher image spatial resolution, increased count rate sensitivity, and higher quantitative capacity. This has resulted in the application of pre-therapeutic 124 I PET(/CT)-based lesion dosimetry (12) (13) (14) (15) (16) (17) .
To date, the only study assessing the dose-response relationship using 124 
I
PET/CT in a larger number of patients was recently published by Jentzen et al. (17) .
Pre-therapeutic 124 I PET/CT lesion AD estimation and toxicity assessment were taken into consideration in patient management, allowing the administration of an by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from optimized therapeutic activity (8.0 ± 4.3 GBq). However, using a fixed activity approach in the absence of toxicity assessment generally results in lower administered 131 I activity than the optimized therapeutic activity. Consequently, it is expected that the lesion AD in the fixed-activity approach are lower than the values published by Jentzen et al. (17) , possibly resulting in more lesions that receive a lesion AD below the established threshold values.
Therefore, the aim of this study was to assess the dose-response-relationship in an approach of a fixed therapeutic 131 I activity in a large group of patients using pretherapeutic 124 I PET/CT lesion dosimetry. Moreover, a new segmentation technique allowing volume estimation down to the PET spatial resolution of 124 I was used (18) . In addition, we assessed the feasibility of performing pre-therapeutic 124 I PET/CT lesion dosimetry as a prognostic tool to predict therapy response in DTC patients in a fixedactivity approach.
MATERIALS AND METHODS

Patient Population
This study was approved by the institutional review board and the requirement to obtain informed consent was waived. In the Maastricht University 
Lesion Volume Calculation
The volume of each lesion with focal uptake, present on both of the pre- Lesions for which either the 24-h or 96-h volume was smaller than 0.15 mL were classified into the small-volume group. For the small-volume group, the lesion volume used for lesion AD estimation was assumed to be equal to the PET spatial resolution volume of 0.15 mL.
Lesion Absorbed Dose Estimation
For each 124 I PET image, lesion uptake was calculated as the average activity concentration (AC) of the segmented volume, corrected for partial volume effect, using measured (absolute) recovery coefficients (18) , which effectively corrects for prompt gamma coincidence effect as well (20) . Assuming identical 124 
The predicted average and minimum lesion AD delivered in radioiodine therapy were estimated by multiplication with the therapeutic 131 I activity.
Therapy Response Assessment
Lesion-based Analysis
Lesions were classified as either thyroid remnant or metastases including lymph node or distant metastases (lymph node, lung, bone). Both the thyroid remnants and metastases were subdivided into a known-volume group and a smallvolume group. Each individual lesion was either defined as completely or incompletely responding by an experienced nuclear medicine physician and medical physicist. Otherwise patients were classified as completely responding. The average patientbased lesion AD was calculated as the mean lesion AD of all radioiodine avid lesions observed per patient.
Patient-based Analysis
Statistics
Statistical analysis was performed using SPSS version 22 (IBM Corp, Armonk, NY, USA). Descriptive data are shown as mean ± standard deviation (median; range).
Differences between two groups were assessed using the Mann-Whitney U test.
Values for P < 0.05 were considered statistically significant. ROC curves were used to test the performance of pre-therapeutic 124 I PET/CT lesion AD for prediction of complete lesion response.
RESULTS
Patient and Lesion Characteristics
Detailed patient characteristics are provided in Table 1 . Out of the in total 67 patients satisfying the inclusion criteria, one patient was excluded as this patient Figure 1 illustrates the calculated lesion AD in radioiodine therapy for both thyroid remnants and metastases for all lesions (including known-and small-volume group), the known-volume group and the small-volume group. Statistically significant higher lesion AD was observed for the completely responding lesions compared to the incompletely responding lesions for all lesions and the known-volume group, but not for the small-volume remnants group. Since there were only 2 incompletely responding lesions in the small-volume metastases group, no statistical tests were performed for this group. Detailed lesion data are provided in the supplemental material. 
Lesion-based Therapy Response
Patient-based Therapy Response
In Table 1 , it can be derived that the incompletely responding patients had a higher TNM status and considerably more radioiodine-avid metastases than the completely responding patients. The median patient-based thyroid remnant lesion AD was higher for the completely responding patients (370 Gy) than the incompletely responding patients (180 Gy) but this was not statistically significant. For metastases, the median patient-based lesion AD was higher for the incompletely responding patients (63 Gy) compared to the completely responding patients (39 Gy), but also not statistically significant. It should be noted that in 7 patients a complete response of all radioiodine-avid lesions was seen at the lesion-based analysis. However, in the patient-based analysis these did not have a complete response as during follow-up new lesions in other anatomical areas were detected with FDG PET/CT, 124 I PET/CT and/or ultrasound in combination with cytology.
DISCUSSION
Maxon et al. (3, 4) demonstrated that a lesion AD threshold of 300 Gy for thyroid remnants and 85 Gy for lymph node metastases was associated with a high complete lesion response rate of 80-90%, establishing the lesion AD as an important by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from quantity for prediction of lesion response in radioiodine treatment. Several groups have identified 124 I PET/CT as a promising modality for performing lesion-based dosimetry (12) (13) (14) (15) (16) (17) . Applying an empirically fixed radioiodine activity approach, Flower et al. (12) were the first to assess lesion AD in 3 patients using 124 I PET. In agreement with our findings, they reported that the administration of fixed activities (3.0-5.5
GBq) resulted in a large variation of lesion AD to both thyroid remnants and involved neck nodes (2.5-33 Gy). In contrast, Erdi et al. (13) Performing this method in 3 patients, they observed a large lesion AD range Gy) at MTA (10-15.5 GBq). Indeed, an approach of MTA applying a maximum blood dose of 2 Gy has been reported to be safe and well-tolerated (25) (26) (27) . Alternatively, several groups have reported on an optimal activity approach using pre-therapeutic 124 I PET/CT lesion AD calculations (14) (15) (16) . In this approach, 131 I therapeutic activity was chosen to achieve lesion AD values above the established threshold values, considering toxicity estimations. Although this approach has been reported to result in change in patient management in 25-50% of DTC patients (14, 16) , the biological effectiveness of dosimetry-guided approaches is not proven yet (1).
To date, the only study assessing the dose-response relationship by means of 124 PET/CT in a larger number of patients was recently published by Jentzen et al. (17) .
Adopting an optimum activity approach, therapy response for thyroid remnant and values. In our study therapeutic activity was almost 4 times lower (median 2.8 GBq, range 1.1 -5.5 GBq) and the estimated lesion AD range extended to the lower lesion AD values. As a result, we observed a statistically significant dose-response relationship confirming a higher calculated lesion AD of completely responding lesions than the incompletely responding lesions. Interestingly, for thyroid remnants we observed a complete lesion response of 89% which is in good agreement with a complete response of 91% found by Jentzen et al (17) , whereas for metastases our study showed a complete lesion response of 69% compared to 88%. These findings suggest that an optimized activity approach might be most beneficial in DTC patients presenting with metastatic disease.
Using ROC curve analysis, we showed that for lesions larger than 0.15 mL, pre-therapeutic 124 I PET/CT lesion dosimetry can be used as a prognostic tool to predict lesion-based 131 I therapy response. For these lesions, the optimal threshold value was 90 Gy for thyroid remnants and 40 Gy for metastases. These values are considerably lower than the accepted threshold values of 300 Gy and 85 Gy.
However, it is important to note that these optimum lesion AD thresholds are defined as the values that give the maximum correct classification combining both sensitivity and specificity. In DTC patient management, a correct prediction of incompletely responding lesions is important. Consequently, for patient's management decisionmaking, higher AD threshold values may be preferred.
Reliable lesion dosimetry requires accurate radioactivity quantification and volume estimation which are affected by the finite spatial resolution of current nuclear medicine imaging equipment (28) , in particular for the small lesion volumes often encountered in DTC patients. In addition, high spatial resolution images by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from obtained by US or CT are considered unreliable due to a lack of differentiation between thyroid tissue and hematoma on these modalities (1) . As a result, lesion AD calculations are considered unreliable for small lesions. Using an established PETbased thresholding method yielding reliable volume estimation for lesions larger than 0.80 mL, Jentzen et al. (17) were able to accurately calculate lesion AD for 24% and 27% of all analyzed thyroid remnants and metastases, respectively. In our study, we used a more advanced segmentation technique allowing volume estimation down to Using voxel-based 3D dose distribution calculations, several studies have reported on the AD distribution heterogeneity within lesions (13) (14) . In these studies, substantial variability in intratumoral AD was observed, possibly resulting in underdosing of tumour subregions and ultimately therapy failure (13) . Although in our study correction for partial volume effect was performed by means of the recovery coefficient, heterogeneity of the lesion AD distribution was not considered since the majority of lesions included in our study were small compared to the 124 I PET spatial resolution.
A limitation of our study was its retrospective nature. However, a high concordance with other studies using 124 I likely confirms the validity of our results. In fact, to date, no prospective randomized study addressing the optimal activity by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from approach has been published and the optimal therapeutic activity is not established yet (1, 2) . The results of our study indicate that pre-therapeutic 124 I PET/CT lesion dosimetry can be used as a prognostic tool to predict lesion response. Therefore, we would strongly advocate cooperative efforts to establish a multi-center prospective 124 I trial to confirm our findings.
Conclusion
This study provides evidence of a statistically significant dose-responserelationship assessed by means of pre-therapeutic 124 I PET/CT dosimetry in both thyroid remnants and metastases. This will be a clinically useful contribution in patient management.
Disclosure
No potential conflict of interest relevant to this article was reported.
by on October 14, 2017. For personal use only. jnm.snmjournals.org Downloaded from
